Heather Wood

Alzheimer disease: [11C]PBB3--a new PET ligand that identifies tau pathology in the brains of patients with AD.

Alzheimer disease: [ 11 C]PBB3—a new PET ligand that identifies tau pathology in the brains of patients with AD

Parkinson disease: 18F-DTBZ PET tracks dopaminergic degeneration in patients with Parkinson disease.

Parkinson disease: 18 F-DTBZ PET tracks dopaminergic degeneration in patients with Parkinson disease

Genetics: Expanding the spectrum of neurological disorders associated with PRRT2 mutations

Genetics: Expanding the spectrum of neurological disorders associated with PRRT2 mutations

Migraine: Familial migraine with aura is associated with a mutation in the TRESK potassium channel

Migraine: Familial migraine with aura is associated with a mutation in the TRESK potassium channel

Parkinson disease: Gut reactions[mdash]can changes in the intestinal microbiome provide new insights into Parkinson disease?

Parkinson disease: Gut reactions—can changes in the intestinal microbiome provide new insights into Parkinson disease?

Neurodegenerative disease: Altered DNA methylation and RNA splicing could be key mechanisms in Huntington disease

Neurodegenerative disease: Altered DNA methylation and RNA splicing could be key mechanisms in Huntington disease

Amyotrophic lateral sclerosis: A hexanucleotide repeat expansion in C9ORF72 links amyotrophic lateral sclerosis and frontotemporal dementia

Amyotrophic lateral sclerosis: A hexanucleotide repeat expansion in C9ORF72 links amyotrophic lateral sclerosis and frontotemporal dementia

Alzheimer disease: Iron[mdash]the missing link between ApoE and Alzheimer disease?

High levels of iron in the brain may predict cognitive decline and progression from mild cognitive impairment (MCI) to Alzheimer disease (AD), according to new research published in Nature Communications. Moreover, the apolipoprotein E ε4 (APOE*ε4) allele—the main genetic risk factor for AD—is associated with increased concentrations of the iron storage protein ferritin in the cerebrospinal fluid (CSF), indicating a possible link between ApoE function and brain iron homeostasis. “It has been known since the 1950s that iron elevation is exaggerated in affected brain regions of people with AD, but there has not previously been a study to investigate what impact iron elevation has on the progression of the disease,” explains study leader Ashley Bush. “We set out to determine whether measures of brain iron in the CSF could predict longitudinal AD outcomes, and might explain the role of ApoE.” The study population included 302 older individuals (average age ~75 years) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort: 91 with normal cognition, 144 with MCI, and 67 with AD. CSF ferritin levels—thought to be a robust indicator of brain iron content— were measured at baseline, and the participants were monitored by means of structural MRI and neuropsychiatric assessments for 7 years. Mean CSF ferritin levels did not differ significantly between the three groups of participants. Within each group, however, high baseline levels of CSF ferritin were associated with increased cognitive decline and hippocampal atrophy over the 7-year follow-up period. In participants with MCI, high CSF ferritin levels at baseline heralded accelerated conversion to AD, with the time to diagnosis of AD being reduced by 3 months for each 1 ng/ml increase in ferritin concentration. The researchers also found an intriguing relationship between ApoE and CSF ferritin. In both APOE*ε4 carriers and non-carriers, levels of ApoE in the CSF correlated positively with ferritin levels. In addition, mean levels of CSF ferritin were increased by more than 20% in the APOE*ε4 carriers compared with the non-carriers. These findings raise the possibility that the APOE*ε4 allele confers susceptibility to AD via brain iron accumulation. Bush and colleagues suggest that lipoprotein trafficking could be a key factor: previous studies have implicated HDL recycling in the regulation of intracellular iron levels, and ApoE4 has a lower affinity for HDL than do the other ApoE isoforms. Therefore, iron retention in the brains of APOE*ε4 carriers could be related to impaired ApoE-mediated trafficking of HDL. “This study has implications for predicting who will develop AD, and is also a strong foundation for future clinical trials into drugs that aim to lower brain iron content,” says Bush. “A phase II study in 1991 showed beneficial effects of the iron chelator deferoxamine in patients with AD, but this study was never followed up—our new study supports the future trialling of iron chelator drugs for AD.”

Pain: New familial pain syndrome caused by TRPA1 mutation

the discovery of a new heritable pain syndrome in a Colombian family, as reported in Neuron, could provide key insights into the roles of the transient receptor potential (trP) cation channels in pain disorders. Previous studies in animal models have strongly implicated the trP channels in pain generation, but FePs (familial episodic pain syndrome) is the first human pain-related channelopathy to be linked to the TRP gene superfamily.

Alzheimer disease: fibrinogen links amyloid with vascular dysfunction.

amyloid-β (aβ) deposition and vascular pathology have both been strongly implicated in the etiology of alzheimer disease (aD), but have tended to be studied largely as separate entities. now, however, researchers at the rockefeller university, new York have proposed a new model of aD pathogenesis that brings these two processes together, with the blood-clotting factor fibrinogen providing the ‘missing link’. in a transgenic mouse model of aD, the team studied blood clotting behavior in the presence of aβ. they focused on fibrinogen, which, during clotting, is cleaved by thrombin to form the insoluble protein fibrin. “an increase in fibrinogen levels has previously been reported to be associated with an increased risk of aD, and fibrinogen deposition in the brain has been described in aD patients and mouse models of the disease,” explains lead author marta Cortes-Canteli. “to analyze clot formation and degradation, we used in vitro and in vivo approaches that complement each other.” the researchers also analyzed postmortem tissue samples from patients with aD. Cortes-Canteli et al. showed that fibrinogen colocalized with aβ in and around blood vessels, thereby alzheimer disease